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ABSTRACT
Study queStion
 What is the association between clarithromycin use 
and cardiovascular outcomes?
MethodS
 In this population based study the authors compared 
cardiovascular outcomes in adults aged 18 or more 
receiving oral clarithromycin or amoxicillin during 
2005-09 in Hong Kong. Based on age within five years, 
sex, and calendar year at use, each clarithromycin user 
was matched to one or two amoxicillin users. The 
cohort analysis included patients who received 
clarithromycin (n=108 988) or amoxicillin (n=217 793). 
The self controlled case series and case crossover 
analysis included those who received Helicobacter 
pylori eradication treatment containing clarithromycin. 
The primary outcome was myocardial infarction. 
Secondary outcomes were all cause, cardiac, or 
non-cardiac mortality, arrhythmia, and stroke.
Study anSwer and liMitationS
 The propensity score adjusted rate ratio of myocardial 
infarction 14 days after the start of antibiotic treatment 
was 3.66 (95% confidence interval 2.82 to 4.76) 
comparing clarithromycin use (132 events, rate 44.4 per 
1000 person years) with amoxicillin use (149 events, 
19.2 per 1000 person years), but no long term increased 
risk was observed. Similarly, rate ratios of secondary 
outcomes increased significantly only with current use 
of clarithromycin versus amoxicillin, except for stroke. 
In the self controlled case analysis, there was an 
association between current use of H pylori eradication 
treatment containing clarithromycin and cardiovascular 
events. The risk returned to baseline after treatment 
had ended. The case crossover analysis also showed 
an increased risk of cardiovascular events during 
current use of H pylori eradication treatment containing 
clarithromycin. The adjusted absolute risk difference 
for current use of clarithromycin versus amoxicillin was 
1.90 excess myocardial infarction events (95% 
confidence interval 1.30 to 2.68) per 1000 patients.
what thiS Study addS
 Current use of clarithromycin was associated with an 
increased risk of myocardial infarction, arrhythmia, 
and cardiac mortality short term but no association 
with long term cardiovascular risks among the Hong 
Kong population.
Funding, CoMpeting intereStS, data Sharing
 ID was funded by grants from the Medical Research 
Council for this project. LS was funded by a grant from 
the Wellcome Trust. The authors have no competing 
interests. No additional data are available.
Introduction
Clarithromycin is a commonly prescribed macrolide 
antibiotic, indicated for respiratory tract infections, 
Mycobacterium avium complex disease in patients with 
human immunodeficiency virus, and skin and soft tis-
sue infections.1 2 Together with amoxicillin or metroni-
dazole and a proton pump inhibitor, clarithromycin is 
also used to treat Helicobacter pylori infections.2  Several 
randomised controlled trials were conducted to explore 
the effects of clarithromycin on the prevention of cardio-
vascular outcomes among patients with cardiovascular 
disease.3-5  Among these, the first randomised controlled 
trial showed that clarithromycin use for three months 
seemed to reduce the risk of cardiovascular outcomes in 
1.5 years.3  However, another randomised controlled 
trial, with follow-up of two years, showed that among 
patients receiving a coronary artery bypass graft, the 
rate of cardiovascular events was not significantly 
reduced with short term clarithromycin treatment com-
pared with placebo.5  On the contrary, a significantly 
higher risk of cardiovascular mortality was reported 
over three years and also a higher all cause mortality 
among patients with coronary heart diseases receiving a 
two week course of clarithromycin once daily compared 
with placebo over six years.4 6 7
In addition to the randomised trials, a cohort study 
reported a substantially higher risk of cardiac death 
associated with use of clarithromycin compared with 
penicillin V over seven day’s follow-up among the gen-
eral population.8  Another cohort study also found a 
higher risk of cardiovascular events one year after treat-
ment with clarithromycin compared with other antibiot-
ics among patients with chronic obstructive pulmonary 
disease and community acquired  pneumonia.9
Given the uncertainty of any increased cardiovascu-
lar risk with clarithromycin, and the finding of an effect 
well beyond the period of use, we carried out an obser-
vational study in Hong Kong to investigate whether 
WhAT IS AlReAdy knoWn on ThIS TopIC
Previous epidemiological studies suggest that clarithromycin is associated with an 
increased risk of serious cardiovascular outcomes
Whether the risk is short term or long term is unclear
WhAT ThIS STudy AddS
In this population based study, current use of clarithromycin was associated with a 
significantly increased risk of myocardial infarction, arrhythmia, and cardiac death
No long term effect was observed
The absolute risk for myocardial infarction and cardiac death was higher in those 
aged 75 or more or with hypertensive diseases or diabetes mellitus and therefore 
caution is needed when selecting antibiotics for these high risk patients
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clarithromycin is associated with cardiovascular out-
comes among the general population. We conducted a 
cohort study using amoxicillin as comparator, a self 
controlled case series, and a case crossover study to 
eliminate between person confounding.
Methods
data sources
The clinical data analysis and reporting system data-
base is managed by the Hospital Authority, which is a 
statutory body responsible for primary, secondary, and 
tertiary public healthcare services in Hong Kong.10  More 
than seven million Hong Kong residents have access to 
healthcare services provided by the Hospital Authority. 
The database contains information on patients’ per-
sonal characteristics and includes details of diagnoses, 
operations, prescriptions, laboratory test results, visits 
to emergency departments and outpatient clinics, and 
hospital stay since 1993. It also contains data on causes 
of death through its internal linkage to regional deaths 
registry from the Immigration Department. The clinical 
data analysis and reporting system generated anony-
mous patient identifiers to protect patient confidential-
ity and to link all medical information such as diagnostic 
and prescribing data. This database has been used to 
conduct high quality epidemiological studies.11-13
Cohort analysis
We identified all adults aged 18 or more and prescribed 
either oral clarithromycin or oral amoxicillin (including 
amoxicillin with clavulanate potassium) between 1 Jan-
uary 2005 and 31 December 2009. Based on age within 
five years, sex, and calendar year at use, we matched 
one clarithromycin user with one or two amoxicillin 
users. In both groups we excluded patients who had 
been prescribed clarithromycin up to four years before 
the date of first antibiotic prescription during the obser-
vation period. However, amoxicillin users could be clas-
sified as using clarithromycin at a later date.
The observation period commenced from the date of 
the first antibiotic prescription (index date) and ended 
at the earliest occurrence of the outcome, death, subse-
quent use of clarithromycin or amoxicillin, or end of 
study (31 December 2012). We assumed that treatment 
was continuous if the gap between scripts was seven 
days or less, as the next script was likely to be prescribed 
for the same indication during follow-up consultation.
The primary outcome was first recorded myocardial 
infarction as the principal diagnosis for a visit to an emer-
gency department or inpatient admission during the 
observation period in multiple follow-up periods. As the 
treatment duration of clarithromycin is generally seven to 
14 days, we classified follow-up periods as current use 
(days 1-14 started on the index date), recent use (days 
15-30), and past use (days 31-90, 91-365, 366-730, or 731-
1095). Secondary outcomes included first recorded princi-
pal diagnosis of arrhythmia; stroke; or all cause, cardiac, 
and non-cardiac mortality during the observation period. 
In each analysis we excluded patients with myocardial 
infarction, arrhythmia, or stroke before the observation 
period. We identified all outcomes using ICD-9 and ICD-10 
codes (international classification of diseases, ninth and 
10th revisions, see supplementary material 1).
Self controlled case series analysis
The self controlled case series method was developed to 
overcome confounding between participants by com-
paring the rate of outcomes in different periods within 
the same individual, and gives a relative incidence esti-
mate.14 The method requires risk windows to be chosen 
a priori and is based on individuals who had both the 
drug of interest and the event. We adopted this case-
only approach to account for differences between par-
ticipants. The exposure of interest was H pylori 
eradication treatment containing clarithromycin. Acute 
infections are known to be associated with an increased 
risk of first myocardial infarction; for this reason we 
chose H pylori because it is a chronic infection unlikely 
to be associated with a period of increased risk of myo-
cardial infarction, and therefore unlikely to lead to a 
spurious association between clarithromycin and risk 
of myocardial infarction.15
We identified patients who received outpatient treat-
ment for H pylori eradication of seven and 14 days’ dura-
tion. Such treatment is defined as coprescription of 
clarithromycin with either amoxicillin or metronidazole 
together with one of the proton pump inhibitors, with 
doses as recommended by the British National Formu-
lary (see supplementary material 2). To avoid including 
a selected group of patients with more severe health 
status at the prescription date, we included patients 
receiving outpatient treatment only. We excluded 
patients who received a clarithromycin prescription or 
inpatient treatment for H pylori before outpatient treat-
ment. Follow-up was censored if participants received a 
prescription for clarithromycin or inpatient treatment 
after outpatient treatment. Similar to the cohort analy-
sis, the event outcomes included myocardial infarction, 
arrhythmia, and stroke. To be included in this cohort, 
patients required a first recorded event as principal 
diagnosis for a visit to an emergency department or 
inpatient admission during the study period (1 January 
2003 to 31 December 2012).
The observation period started from one year after the 
patients entered the database, and we censored fol-
low-up at the earliest of end of the study (31 December 
2012), death, or one of the censoring events. We consid-
ered patients to be ineligible if they had a history of 
H pylori eradication treatment or an event before the 
observation period. Similar to the cohort analysis, we 
defined several risk windows: current use (days 1-14 from 
the index date), recent use (days 15-30), and past use 
(days 31-90, 91-365, 366-730, or 731-1095). We classified all 
other periods as baseline, except for the 14 day window 
of risk before drug use. As the self controlled case series 
requires an assumption that an event should not alter 
the probability of subsequent drug use, we removed 
from the baseline periods a 14 day risk window before 
the use of H pylori eradication treatment. This avoids the 
potential for bias whereby the outcome of interest (myo-
cardial infarction, arrhythmia, stroke) may temporarily 
alter the likelihood of the drug being prescribed.14  When 
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a gap in treatment was seven days or less we assumed 
treatment to have been continued. In addition to the 
standard self controlled case series, we also analysed 
the data using a non-parametric self controlled case 
series. This method, unlike that of the  standard self con-
trolled case series, does not require predefinition of sev-
eral risk windows, and it estimates relative incidence 
functions showing how incidence changes with time.16
data validation
To determine the validity of the recorded diagnoses, we 
reviewed the original clinical records in the computer 
based clinical management system among a sample of 
patients from the Hong Kong west cluster. In Hong Kong, 
all hospital admissions, outpatient clinic records, labo-
ratory test results, and radiological images in the public 
health system have been recorded in the clinical man-
agement system since 1996. The Hong Kong west cluster, 
one of the seven administrative hospital clusters of the 
Hospital Authority, provides public healthcare services 
to 530 000 residents (8% of the Hong Kong population) 
in that region and allows cross-cluster referrals from 
other cluster regions.17  One of the two university teach-
ing hospitals in the Hong Kong west cluster—the Queen 
Mary Hospital—provides tertiary and quaternary care.17
Through the clinical data analysis and reporting sys-
tem we identified cases of myocardial infarction and 
arrhythmia among our study cohort. A cardiologist (CS) 
reviewed the records, including clinical notes, electro-
cardiograms, laboratory test results, and computed 
tomograms. We identified cases of stroke from another 
study cohort (WCY Lau, personal communication, 
2015). The clinical notes and results from radiology, 
computed tomography, or magnetic resonance imaging 
of the brain were reviewed. We defined the correspond-
ing positive predictive values with binominal exact 95% 
confidence intervals as the proportion of the number of 
patients with verified outcomes after review against the 
total number of patients with the specific diagnosis in 
the clinical data analysis and reporting system.
Statistical and sensitivity analyses
After initial adjustment for age, sex, and history of the 
event of interest, we used Poisson regression to esti-
mate the rate ratios for clarithromycin users compared 
with amoxicillin users during current, recent, and past 
use. To control for confounding we also adjusted for 
propensity score. We derived propensity scores from 
conditional logistic regression to represent the condi-
tional probability of drug use given the covariates (see 
supplementary material 3). To identify a group within 
which valid comparisons were possible, we further 
restricted the cohort to those participants whose pro-
pensity scores were within the overlapping region of the 
distributions of the clarithromycin and amoxicillin 
groups. To further reduce the potential effects of 
unmeasured confounding, we excluded those with 
extreme scores in the upper or lower tail of the propen-
sity score distribution to avoid bias owing to missing 
information on important risk factors for adverse out-
comes.18  To allow establishment of the cut-points for 
trimming we therefore constructed 20 categories of 5% 
each for the distribution of scores.19  In the primary 
analysis we trimmed the first and 20th propensity score 
strata (see supplementary material 4). Along with other 
initial adjustment variables, we also used the estimated 
propensity score as an adjustment variable in the Pois-
son regression in the final analysis. We conducted a 
sensitivity analysis for follow-up periods in current 
(days 1-7 from the index date) and recent use (days 8-30). 
We also performed a sensitivity analysis without 
 trimming propensity score strata. For the analyses of 
causes of death, patients with unknown cause of death 
at the time of death were censored but not classified as 
having an outcome. We also conducted a subgroup 
analysis to evaluate the risk of cardiovascular outcomes 
for age, sex, and history of hypertensive diseases or dia-
betes mellitus. Moreover, we estimated the propensity 
score adjusted absolute difference in risk of myocardial 
infarction, arrhythmia, stroke, and cardiac death for 
clarithromycin use as adjusted rate ratios minus 1, fol-
lowed by the multiplication of the crude incidence rates 
among patients using amoxicillin for each 1000 
patients.20 21 Similarly, we estimated the propensity 
score adjusted absolute differences in subgroups. All 
statistical tests were two sided and we considered P val-
ues at the 5% level to be statistically significant.
For the self controlled case series analysis, we esti-
mated incidence rate ratios using conditional Poisson 
regression, comparing the rate of events during risk win-
dows with the rate during baseline periods. We further 
divided all periods into single year bands to adjust for 
age effect. As myocardial infarction might increase mor-
tality in the short term, the observation period would be 
censored at random and thus affect the assumption of 
event independence. As the self controlled case series 
analysis might be prone to bias if the outcome leads to 
censoring of the observation period, we also performed 
a post hoc case crossover analysis, which is not vulnera-
ble to this limitation of the self controlled case series. 
The case crossover design is applied for studies investi-
gating the association between transient drug use and 
outcome with abrupt time of onset.22  We estimated odds 
ratios using conditional logistic regression, comparing 
drug use before the event (current period) with that at 
other earlier control periods within patients. The length 
of current and control periods were both 14 days. We 
used 100 control periods at maximum to improve preci-
sion and increase power.22 As the temporal trend of pre-
scriptions for H pylori eradication treatment containing 
clarithromycin was stable throughout the study period 
we did not adjust time trends in drug use for case cross-
over analysis (see supplementary material 5).
In the non-parametric self controlled case series 
analysis we estimated two incidence rate ratio func-
tions, using myocardial infarction as an example to 
illustrate the incidence rate ratio over time; a function 
that represents an incidence rate ratio during current 
use of clarithromycin and an incidence rate ratio func-
tion in the washout period up to three years after treat-
ment ended. In this method, age effect was also 
adjusted for without prespecifying age groups.
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For quality assurance, two investigators (AW and CC) 
independently conducted the statistical analyses using 
SAS software, version 9.3 (SAS Institute) and R version 
3.2.0 (www.R-project.org).
Results
data validation
A total of 1999 cases of myocardial infarction and 712 of 
arrhythmia were identified in the clinical data analysis 
and reporting system from cohort and self controlled case 
series analysis. Of these, we identified 151 cases of myo-
cardial infarction and 44 of arrhythmia from the Hong 
Kong west cluster. In another study cohort, 1054 cases of 
stroke were identified in the analysis. Among these, 90 
were from the Hong Kong west cluster. The overall posi-
tive predictive values for myocardial  infarction (129/151), 
arrhythmia (20/44), and stroke (82/90) were 85.4% (95% 
confidence interval 78.8% to 90.6%), 45.5% (30.4% to 
61.2%), and 91.1% (83.2% to 96.1%), respectively.
the risk of cardiovascular outcomes
Figure 1  shows the flow of the cohort in the study. We 
matched 108 988 clarithromycin users with 217 793 
amoxicillin users. Table 1 shows the baseline character-
istics of the full cohort (see supplementary material 6 for 
characteristics of the trimmed cohort). Supplementary 
material 7 illustrates the propensity score distributions 
before and after trimming the propensity score. Com-
pared with amoxicillin users, clarithromycin users were 
more likely to have a medical history of chronic obstruc-
tive pulmonary disease, obesity, hepatic  problems, and 
heart failure. They were also more likely to have pre-
scriptions for insulin, oral corticosteroids, proton pump 
inhibitors, and H2 receptor blockers, and to have visited 
an emergency department in the past year.
After exclusion of propensity score stratum 1 and 20, 
the cohort included 95 797 clarithromycin users and 
198 305 amoxicillin users. Among these participants, 
583 clarithromycin users and 1375 amoxicillin users had 
the primary outcome of myocardial infarction during 
follow-up.
Figure 2  and table 2 show the adjusted rate ratios of 
all outcomes associated with current, recent, and past 
use of clarithromycin compared with use of amoxicillin. 
For myocardial infarction, the initial adjusted rate ratio 
for current use of clarithromycin was 2.72 (95% 
 confidence interval 2.15 to 3.44), with a propensity score 
adjusted rate ratio of 3.66 (2.82 to 4.76) compared with 
use of amoxicillin. For the secondary outcomes of 
arrhythmia and stroke, the initial adjusted rate ratios 
for current use of clarithromycin were 2.13 (1.25 to 3.63) 
and 1.05 (0.79 to 1.41), respectively, with fully propensity 
score adjusted rate ratios of 2.22 (1.22 to 4.06) and 1.11 
(0.80 to 1.54) compared with current use of amoxicillin. 
For all cause mortality, the initial adjusted rate ratio for 
current use of clarithromycin was 2.41 (2.27 to 2.56), 
with a propensity score adjusted rate ratio of 1.97 (1.83 
to 2.11) compared with current use of amoxicillin. For 
cardiac mortality, the initial rate ratio for use of clari-
thromycin was 1.93 (1.61 to 2.30), with a propensity 
score adjusted rate ratio of 1.67 (1.36 to 2.06) compared 
with current use of amoxicillin. For non-cardiac mortal-
ity, the initial adjusted rate ratio associated with cur-
rent use of clarithromycin was 2.59 (2.42 to 2.76), with 
propensity score adjusted rate ratio of 2.10 (1.94 to 2.27). 
No statistically significant increased rate ratios of all 
outcomes were found for recent and past use of 
 clarithromycin compared with recent and past use of 
amoxicillin. In the sensitivity analysis when we 
included patients with scores in the first and 20th 5% 
stratums, similar results were obtained for all outcomes 
of interest in the primary analysis (see supplementary 
material 8).
Similar results were obtained for all outcomes of 
interest in the primary analysis when the sensitivity 
analysis was conducted, stratifying follow-up periods 
for current use (days 1-7) and recent use (days 8-30) of 
clarithromycin compared with amoxicillin (see supple-
mentary material 9). The increased cardiovascular risk 
was largely confined to current use (days 1-7) of clari-
thromycin versus amoxicillin. Subgroup analysis 
showed that rate ratios for myocardial infarction, 
arrhythmia, and cardiac death were comparable 
between men and women. The highest absolute risk dif-
ferences were for myocardial infarction and cardiac 
death in patients aged 75 or more and for those with a 
history of hypertensive diseases or diabetes. Owing to 
the lack of power, evidence was lacking for an increased 
risk of arrhythmia among patients aged 65 or more and 
those with a history of hypertensive diseases or diabe-
tes (see supplementary material 10). The propensity 
score adjusted absolute risk difference for current use of 
clarithromycin compared with amoxicillin was 1.90 
excess myocardial infarction events (95% confidence 
interval 1.30 to 2.68) per 1000 patients. Also, 0.95 excess 
cardiac deaths (0.51 to 1.51) and 0.20 excess arrhythmia 
events (0.04 to 0.49) per 1000 patients occurred in cur-
rent users of clarithromycin compared with current 
users of amoxicillin.
In the self controlled case series analysis, for those 
patients who received outpatient treatment for eradica-
tion of H pylori we identified 740 patients who had inci-
dent myocardial infarction during the study period, 309 
who had incident arrhythmia, and 2279 who had inci-
dent stroke. Table 3 presents the incidence rate ratios 
Patients receiving amoxicillin (n=1 194 807)Patients receiving clarithromycin (n=139 770)
Matching
Clarithromycin (n=108 990)
Amoxicillin (n=618 814)
Study cohort
Clarithromycin (n=108 988)
Amoxicillin (n=217 793)
Excluded (n=575 993):
  Parental dose forms (n=237 403)
  Clarithromycin prescription before
    index date (n=83 561)
  Invalid demographics or age <18 years
    (n=190 238)
  Incomplete records (n=64 791)
Excluded (n=30 780):
  Parental dose forms (n=2698)
  Clarithromycin prescription before
    index date (n=9432)
  Invalid demographics or age <18 years
    (n=15 572)
  Incomplete records (n=3078)
Fig 1 | inclusion and exclusion of participants in cohort analysis
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table 1 | Baseline characteristics of full cohort at index date in cohort analysis. Values are numbers (percentages) unless 
stated otherwise
Characteristics
Clarithromycin users 
(n=108 988)
amoxicillin users 
(n=217 793)
Median age (years) 60.0 60.0
Men 57 114 (52.4) 114 063 (52.4)
Calendar month of drug use:
 January 9387 (8.6) 19 950 (9.2)
 February 9046 (8.3) 18 512 (8.5)
 March 10 163 (9.3) 20 961 (9.6)
 April 9387 (8.6) 18 928 (8.7)
 May 9353 (8.6) 18 992 (8.7)
 June 8919 (8.2) 18 219 (8.4)
 July 9077 (8.3) 18 006 (8.3)
 August 9080 (8.3) 17 622 (8.1)
 September 8539 (7.8) 16 858 (7.7)
 October 8517 (7.8) 16 370 (7.5)
 November 8541 (7.8) 16 289 (7.5)
 December 8979 (8.2) 17 086 (7.9)
Medical history:
 Chronic obstructive pulmonary disease 7528 (6.9) 6946 (3.2)
 Obesity 339 (0.3) 399 (0.2)
 Diabetes 10 761 (9.9) 16 287 (7.5)
 Thyroid disorders 1813 (1.7) 3457 (1.6)
 Hyperlipidaemia 4348 (4.0) 6749 (3.1)
 Hypertensive diseases 17 788 (16.3) 28 067 (12.9)
 Coronary heart disease 8200 (7.5) 12 883 (5.9)
 Cerebrovascular diseases 8696 (8.0) 13 032 (6.0)
 Arterial disease 2132 (2.0) 2970 (1.4)
 Cardiomyopathy 382 (0.4) 545 (0.3)
 Heart failure 5707 (5.2) 6791 (3.1)
 Valve disorders 663 (0.6) 1211 (0.6)
 Arrhythmia and conduction disorders 6359 (5.8) 10 404 (4.8)
 Hypertensive renal disease 404 (0.4) 475 (0.2)
 Renal failure 2675 (2.5) 3146 (1.4)
 Oesophageal varices 274 (0.3) 192 (0.1)
 Hepatic failure, liver fibrosis, and cirrhosis 1572 (1.4) 1764 (0.8)
 Schizophrenia, delusional disorders, and psychosis 2114 (1.9) 4286 (2.0)
 Bipolar disorder 226 (0.2) 488 (0.2)
 Depression 3096 (2.8) 5386 (2.5)
Prescription in past year:
 Angiotensin receptor blocker/angiotensin converting enzyme inhibitor 16 573 (15.2) 28 559 (13.1)
 Calcium channel blockers 22 098 (20.3) 40 597 (18.6)
 Loop diuretics 10 137 (9.3) 12 091 (5.6)
 Other diuretics 8989 (8.3) 17 691 (8.1)
 β blockers 19 295 (17.7) 36 691 (16.9)
 Anti-arrhythmics class I and II 1217 (1.1) 1677 (0.8)
 Digoxin 2737 (2.5) 3760 (1.7)
 Nitrates 9932 (9.1) 14 492 (6.7)
 Platelet inhibitors 17 917 (16.4) 28 159 (12.9)
 Anticoagulants 3768 (3.5) 5830 (2.7)
 Peripheral vasodilators 974 (0.9) 1455 (0.7)
 Lipid lowering drugs 9585 (8.8) 16 979 (7.8)
 Insulin 3737 (3.4) 4228 (1.9)
 Oral hypoglycaemic agent 13 080 (12.0) 23 720 (10.9)
 Antidepressants 5536 (5.1) 9359 (4.3)
 Antipsychotics 4508 (4.1) 7559 (3.5)
 Oral corticosteroids 9945 (9.1) 9600 (4.4)
 Non-steroidal anti-inflammatory drugs 18 856 (17.3) 40 139 (18.4)
 Proton pump inhibitors/H2 receptor blockers 55 615 (51.0) 44 190 (20.3)
Median No (interquartile range) of prescriptions used in past year 17 (4-44) 12 (2-31)
Healthcare use in past year:
 Median No (interquartile range) of outpatient visits 5 (2-10) 5 (1-9)
 Median No (interquartile range) of inpatient stays 1 (0-2) 0 (0-1)
 Median No (interquartile range) of emergency department visits 1 (0-2) 0 (0-1)
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for different risk windows. For current use of H pylori 
eradication treatment, the incidence rate ratios for 
myocardial infarction and arrhythmia were 3.38 (1.89 to 
6.04) and 5.07 (2.19 to 11.72), respectively. In line with 
the cohort analysis, the risk of cardiovascular outcomes 
was not increased during all other periods of clarithro-
mycin use to the end of three years. The case crossover 
analysis also showed an increased risk of myocardial 
infarction and arrhythmia during current use of H pylori 
eradication treatment that contained clarithromycin 
(table 3 ). For stroke, no increased risk was observed in 
both self controlled case series and case crossover stud-
ies. Figure 3 presents the incidence rate ratio functions 
estimated from the non-parametric self controlled case 
series analysis. The rates changed over time within the 
14 days of current H pylori eradication treatment. The 
risk of myocardial infarction was increased during this 
period and the risk reduced to a baseline rate around 
the end of treatment. The incidence rate ratio of myo-
cardial infarction after H pylori eradication treatment 
did not change over time, but rather stayed at the base-
line rate (fig 3).
discussion
In this territory wide cohort study, no increased risk of 
cardiovascular outcomes was observed long term with 
clarithromycin treatment compared with amoxicillin 
treatment but there was a suggestion of an increased 
cardiovascular risk during and immediately after clari-
thromycin use. A case only approach was employed to 
investigate the association between clarithromycin as 
part of H pylori eradication treatment and cardiovascu-
lar outcomes. Similarly, we observed that the risk of 
myocardial infarction and arrhythmia was only 
increased during current use of H pylori eradication 
treatment containing clarithromycin, and no increased 
risk was observed long term.
interpretation and comparison with other studies
In an attempt to minimise indication bias in the cohort 
analysis, we selected amoxicillin as the comparator 
group, as it is used for similar indications to clarithromy-
cin. However, the characteristics of the clarithromycin 
users at the index date were systematically different 
from those of amoxicillin users—a higher proportion of 
those taking clarithromycin had chronic obstructive pul-
monary disease, diabetes, hepatic problems, coronary 
heart disease, and heart failure. These patients were 
also more likely to use a proton pump inhibitor, which 
has been identified as a marker of poor prognosis in pre-
vious work.23 It is possible that clinicians opt for clari-
thromycin in frailer patients. Although the presence of 
channeling bias seems to be implied, the underlying 
differences in health between the treatment groups did 
not appear to fully explain the noticeably increased 
short term cardiovascular risk with clarithromycin use 
based on the propensity score adjustment method.
A higher rate ratio of non-cardiac mortality was also 
found in the cohort analysis for current use of clarithro-
mycin compared with amoxicillin despite adjustment 
for propensity score, which would not be predicted by 
the study hypothesis. As a negative control outcome, 
this may indicate bias. This further suggests that, com-
pared with amoxicillin, clarithromycin was more likely 
to be prescribed for frailer patients or for those with 
more severe infections. However, it is anticipated that 
all between person confounding factors that remain 
stable in a cohort study design could be removed over 
the study period by using self controlled case series 
methodology. Using this analysis method and focusing 
on patients treated for H pylori infection, which is not 
an acute infection, we still found an increased risk of 
myocardial infarction and arrhythmia during current 
use of H pylori eradication treatment containing clari-
thromycin, with no increased risk observed after treat-
ment had ended.
Myocardial infarction
  Days 1-14
  Days 15-30
  Days 31-90
  Days 91-365
  Days 366-730
  Days 731-1095
Arrhythmia
  Days 1-14
  Days 15-30
  Days 31-90
  Days 91-365
  Days 366-730
  Days 731-1095
Stroke
  Days 1-14
  Days 15-30
  Days 31-90
  Days 91-365
  Days 366-730
  Days 731-1095
All cause mortality
  Days 1-14
  Days 15-30
  Days 31-90
  Days 91-365
  Days 366-730
  Days 731-1095
Cardiac mortality
  Days 1-14
  Days 15-30
  Days 31-90
  Days 91-365
  Days 366-730
  Days 731-1095
Non-cardiac mortality
  Days 1-14
  Days 15-30
  Days 31-90
  Days 91-365
  Days 366-730
  Days 731-1095
3.66 (2.82 to 4.76)
1.06 (0.44 to 2.60)
1.10 (0.63 to 1.92)
0.90 (0.65 to 1.24)
1.17 (0.86 to 1.59)
1.01 (0.72 to 1.40)
2.22 (1.22 to 4.06)
0.86 (0.31 to 2.37)
0.93 (0.50 to 1.74)
1.00 (0.64 to 1.56)
1.17 (0.73 to 1.86)
1.17 (0.69 to 2.00)
1.11 (0.80 to 1.54)
1.19 (0.67 to 2.12)
1.35 (0.98 to 1.85)
0.97 (0.79 to 1.18)
1.09 (0.90 to 1.34)
1.17 (0.96 to 1.43)
1.97 (1.83 to 2.11)
0.96 (0.86 to 1.08)
0.78 (0.70 to 0.87)
0.96 (0.88 to 1.06)
1.03 (0.92 to 1.16)
1.03 (0.88 to 1.20)
1.67 (1.36 to 2.06)
1.42 (0.99 to 2.04)
0.80 (0.57 to 1.13)
0.91 (0.69 to 1.20)
0.97 (0.68 to 1.36)
0.78 (0.51 to 1.19)
2.10 (1.94 to 2.27)
0.98 (0.86 to 1.11)
0.81 (0.72 to 0.91)
1.02 (0.92 to 1.14)
1.13 (0.98 to 1.30)
1.14 (0.94 to 1.38)
0 1 52 3 4
Rate ratio (95% CI)Rate ratio (95% CI)
Fig 2 | propensity score adjusted rate ratios of all outcomes with clarithromycin use 
compared with amoxicillin use
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table 2 | propensity score adjusted rate ratios of all outcomes with clarithromycin use compared with amoxicillin use
outcomes by 
treatment duration
Before propensity score adjustment
analysis restricted to patients with 
comparable propensity scores
no of 
patients
Mean follow-up 
(days)
no of 
events rate ratio (95% Ci)
no of 
patients
no of 
events rate ratio (95% Ci)
Myocardial infarction
Days 1-14:
 Clarithromycin 102 514 10.6 132 2.72 (2.15 to 3.44) 90 411 117 3.66 (2.82 to 4.76)
 Amoxicillin 204 855 13.9 149 — 186 888 132 —
Days 15-30:
 Clarithromycin 70 184 15.7 11 1.23 (0.62 to 2.43) 62 803 7 1.06 (0.44 to 2.60)
 Amoxicillin 200 770 15.7 34 — 183 379 25 —
Days 31-90:
 Clarithromycin 67 707 57.8 23 1.31 (0.82 to 2.12) 60 826 19 1.10 (0.63 to 1.92)
 Amoxicillin 193 522 57.7 67 — 177 022 59 —
Days 91-365:
 Clarithromycin 63 155 251.4 67 1.15 (0.87 to 1.52) 57 197 56 0.90 (0.65 to 1.24)
 Amoxicillin 180 522 252.2 221 — 165 594 198 —
Days 366-730:
 Clarithromycin 53 614 339.8 72 1.23 (0.94 to 1.61) 49 126 64 1.17 (0.86 to 1.59)
 Amoxicillin 153 426 336.2 223 — 141 460 205 —
Days 731-1095:
 Clarithromycin 46 586 344.4 62 1.18 (0.88 to 1.57) 42 977 57 1.01 (0.72 to 1.40)
 Amoxicillin 130 664 340.7 198 — 120 937 182 —
arrhythmia
Days 1-14:
 Clarithromycin 107 200 10.5 23 2.13 (1.25 to 3.63) 94 319 20 2.22 (1.22 to 4.06)
 Amoxicillin 214 222 13.9 33 — 195 129 31 —
Days 15-30:
 Clarithromycin 72 574 15.7 7 0.97 (0.42 to 2.23) 64 826 5 0.86 (0.31 to 2.37)
 Amoxicillin 209  867 15.7 27 — 191 386 24 —
Days 31-90:
 Clarithromycin 69 933 57.7 17 0.98 (0.58 to 1.68) 62 723 14 0.93 (0.50 to 1.74)
 Amoxicillin 202 075 57.7 66 — 184 556 59 —
Days 91-365:
 Clarithromycin 65 072 250.9 41 1.42 (0.99 to 2.04) 58 854 30 1.00 (0.64 to 1.56)
 Amoxicillin 188 113 252.0 110 — 172 294 97 —
Days 366-730:
 Clarithromycin 55 081 339.6 36 1.28 (0.87 to 1.88) 50 425 28 1.17 (0.73 to 1.86)
 Amoxicillin 159 549 335.8 100 — 146 877 88 —
Days 731-1095:
 Clarithromycin 47 788 344.2 28 1.23 (0.80 to 1.91) 44 042 22 1.17 (0.69 to 2.00)
 Amoxicillin 135 506 340.4 81 — 125 218 69 —
Stroke
Days 1-14:
 Clarithromycin 90 225 10.8 63 1.05 (0.79 to 1.41) 80 236 54 1.11 (0.80 to 1.54)
 Amoxicillin 180 324 13.9 176 — 164 634 163 —
Days 15-30:
 Clarithromycin 63 829 15.7 21 1.20 (0.73 to 1.97) 57 412 18 1.19 (0.67 to 2.12)
 Amoxicillin 177 173 15.7 61 — 161 908 55 —
Days 31-90:
 Clarithromycin 61 804 58.0 79 1.57 (1.20 to 2.05) 55 768 64 1.35 (0.98 to 1.85)
 Amoxicillin 171 158 57.9 176 — 156 616 159 —
Days 91-365:
 Clarithromycin 57 983 252.4 178 1.09 (0.92 to 1.29) 52 658 151 0.97 (0.79 to 1.18)
 Amoxicillin 160 206 253.2 573 — 146 937 521 —
Days 366-730:
 Clarithromycin 49 616 341.0 177 1.12 (0.95 to 1.33) 45 525 154 1.09 (0.90 to 1.34)
 Amoxicillin 137 150 337.6 555 — 126 440 505 —
Days 731-1095:
 Clarithromycin 43 398 345.2 172 1.14 (0.96 to 1.36) 40 064 154 1.17 (0.96 to 1.43)
 Amoxicillin 117 679 341.7 524 — 108 918 473 —
(Continued)
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table 2 | propensity score adjusted rate ratios of all outcomes with clarithromycin use compared with amoxicillin use
outcomes by 
treatment duration
Before propensity score adjustment
analysis restricted to patients with 
comparable propensity scores
no of 
patients
Mean follow-up 
(days)
no of 
events rate ratio (95% Ci)
no of 
patients
no of 
events rate ratio (95% Ci)
all cause mortality
Days 1-14:
 Clarithromycin 108 988 10.5 1948 2.41 (2.27 to 2.56) 95 797 1471 1.97 (1.83 to 2.11)
 Amoxicillin 217 793 13.9 2562 — 198 305 2127 —
Days 15-30:
 Clarithromycin 73 526 15.7 569 1.36 (1.24 to 1.50) 65 641 413 0.96 (0.86 to 1.08)
 Amoxicillin 213 280 15.7 1611 — 194 421 1352 —
Days 31-90:
 Clarithromycin 70 820 57.7 659 1.11 (1.02 to 1.21) 63 492 506 0.78 (0.70 to 0.87)
 Amoxicillin 205 318 57.7 2283 — 187 445 1920 —
Days 91-365:
 Clarithromycin 65 875 250.9 836 1.28 (1.18 to 1.39) 59 563 669 0.96 (0.88 to 1.06)
 Amoxicillin 191 071 251.9 2563 — 174 938 2251 —
Days 366-730:
 Clarithromycin 55 750 339.4 505 1.30 (1.18 to 1.44) 51 023 418 1.03 (0.92 to 1.16)
 Amoxicillin 161 952 335.8 1544 — 149 045 1392 —
Days 731-1095:
 Clarithromycin 48 329 344.1 283 1.20 (1.05 to 1.38) 44 534 241 1.03 (0.88 to 1.20)
 Amoxicillin 137 515 340.3 954 — 127 043 853 —
Cardiac mortality‡§
Days 1-14:
 Clarithromycin 108 988 10.5 201 1.93 (1.61 to 2.30) 95 797 152 1.67 (1.36 to 2.06)
 Amoxicillin 217 793 13.9 315 — 198 305 279 —
Days 15-30:
 Clarithromycin 73 526 15.7 55 1.46 (1.07 to 1.99) 65 641 43 1.42 (0.99 to 2.04)
 Amoxicillin 213 280 15.7 152 — 194 421 130 —
Days 31-90:
 Clarithromycin 70 820 57.7 54 1.01 (0.75 to 1.36) 63 492 43 0.80 (0.57 to 1.13)
 Amoxicillin 205 318 57.7 219 — 187 445 194 —
Days 91-365:
 Clarithromycin 65 875 250.9 84 1.15 (0.90 to 1.46) 59 563 70 0.91 (0.69 to 1.20)
 Amoxicillin 191 071 251.9 313 — 174 938 273 —
Days 366-730:
 Clarithromycin 55 750 339.4 53 1.10 (0.81 to 1.49) 51 023 46 0.97 (0.68 to 1.36)
 Amoxicillin 161 952 335.8 210 — 149 045 189 —
Days 731-1095:
 Clarithromycin 48 329 344.1 35 0.94 (0.65 to 1.36) 44 534 29 0.78 (0.51 to 1.19)
 Amoxicillin 137 515 340.3 160 — 127 043 144 —
non-cardiac mortality
Days 1-14:
 Clarithromycin 108 988 10.5 1687 2.59 (2.42 to 2.76) 95 797 1271 2.10 (1.94 to 2.27)
 Amoxicillin 217 793 13.9 2067 — 198 305 1695 —
Days 15-30:
 Clarithromycin 73 526 15.7 490 1.40 (1.26 to 1.56) 65 641 357 0.98 (0.86 to 1.11)
 Amoxicillin 213 280 15.7 1335 — 194 421 1112 —
Days 31-90:
 Clarithromycin 70 820 57.7 555 1.16 (1.05 to 1.28) 63 492 424 0.81 (0.72 to 0.91)
 Amoxicillin 205 318 57.7 1808 — 187 445 1492 —
Days 91-365:
 Clarithromycin 65 875 250.9 655 1.39 (1.27 to 1.53) 59 563 517 1.02 (0.92 to 1.14)
 Amoxicillin 191 071 251.9 1799 — 174 938 1561 —
Days 366-730:
 Clarithromycin 55 750 339.4 387 1.43 (1.27 to 1.61) 51 023 318 1.13 (0.98 to 1.30)
 Amoxicillin 161 952 335.8 1052 — 149 045 943 —
Days 731-1095:
 Clarithromycin 48 329 344.1 195 1.30 (1.11 to 1.53) 44 534 168 1.14 (0.94 to 1.38)
 Amoxicillin 137 515 340.3 592 — 127 043 532 —
Days 1-14=current use; days 15-30=recent use; days 31-1095=past use.
*Initial adjustment for age and sex before propensity score adjustment.
‡Initial adjustment for age, sex, and history of myocardial infarction and arrhythmia before propensity score adjustment. 
†Full adjustment for age, sex, and propensity score in analyses restricted to patients with comparable propensity scores.
§Full adjustment for age, sex, history of myocardial infarction and arrhythmia, and propensity score in analyses restricted to patients with comparable 
propensity scores.
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Although some patients with H pylori could have 
severe gastrointestinal bleeding that might precipitate 
myocardial infarction,24 it was unlikely to have affected 
the findings in this study. We only included patients 
receiving outpatient H pylori eradication treatment con-
taining clarithromycin who were unlikely to have severe 
gastrointestinal bleeding. Therefore, we concluded that 
the increase in cardiovascular risk short term was not 
attributable to the infection that prompted antibiotic 
treatment, but rather to the use of clarithromycin. In 
recent years, case reports have also suggested clarithro-
mycin has proarrhythmic potency that leads to QT pro-
longation, torsades de pointes,25-27  and other 
arrhythmias.28  This hypothesis could be explained by 
blockade of the potassium channel and therefore result 
in a prolonged duration of the action potential and 
early after depolarisation.25  Such a mechanism would 
be consistent with a short increased risk of arrhythmia, 
in keeping with the findings of our cohort and self con-
trolled case series analysis. Given the increased risk of 
myocardial infarction found in our study, QT prolonga-
tion alone might not fully explain the cardiac effect, 
thus requiring further investigation. A recent case 
report suggested that clarithromycin might cause rup-
ture of coronary plaque resulting from triggering of the 
allergic response.29 Possibly, arrhythmia may also have a 
role in plaque rupture leading to myocardial infarction.
A recent cohort study investigating the association 
between current use of clarithromycin and cardiac 
death in Denmark also reported a higher significant rate 
ratio of 1.76 (95% confidence interval 1.08 to 2.85).8 
However, the study outcome was composite causes of 
death including, for example, myocardial infarction, 
arrhythmia, heart failure, and cardiomyopathy. 
 Therefore, given the increased risk of composite causes 
of cardiac death, we cannot exclude the possibility that 
the cardiac effect may be explained by other mecha-
nism pathways. Another observational Danish study 
reported no significant increase in the risk of a compos-
ite end point, including cardiovascular mortality and 
myocardial infarction among patients with ischaemic 
heart disease receiving H pylori eradication treatment 
during a follow-up period of five years.30  In addition to 
cardiac mortality, we chose specific separate outcomes 
such as myocardial infarction and arrhythmia to inves-
tigate the cardiovascular effect associated with clari-
thromycin. In line with two Danish studies, our study 
showed that the risk of all cardiovascular outcomes of 
interest was increased during current use of clarithro-
mycin, and no long term risk was observed.8 30
In contrast with our study, some observational stud-
ies reported cardiovascular risk associated with the use 
of clarithromycin long term, which is of concern 
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Fig 3 | incidence rate ratio functions of myocardial 
infarction estimated by non-parametric self controlled case 
series method and 95% confidence bands
table 3 | patient characteristics, incidence rate ratios (case series analysis), and odds 
ratios (case crossover analysis) of myocardial infarction, arrhythmia, and stroke. Values 
in brackets are 95% confidence intervals unless stated otherwise
Characteristics Self controlled case series Case crossover
Myocardial infarction
No in sample 740 308
Median age (years)* 65.0 73.3
Men (%) 508 (68.7) 201 (65.3)
14 days before treatment 0.81 (0.26 to 2.53) —
Days after treatment:
 1-14 3.38 (1.89 to 6.04) 2.20 (1.23 to 3.95)
 15-30 0.78 (0.25 to 2.42) —
 31-90 0.89 (0.51 to 1.56) —
 91-365 1.08 (0.83 to 1.41) —
 366-730 1.05 (0.82 to 1.35) —
 731-1095 0.96 (0.73 to 1.25) —
arrhythmia
No in sample 309 143
Median age (years) 64.0 71.1
Men (%) 163 (52.8) 86 (60.1)
14 days before treatment 2.45 (0.77 to 7.80) —
Days after treatment:
 1-14 5.07 (2.19 to 11.72) 2.49 (1.09 to 5.69)
 15-30 0.00 (0.00 to INF) —
 31-90 1.94 (0.98 to 3.85) —
 91-365 1.61 (1.05 to 2.45) —
 366-730 1.07 (0.69 to 1.67) —
 731-1095 1.02 (0.78 to 1.86) —
Stroke
No in sample 2279 852
Median age (years) 66.0 73.0
Men (%) 1295 (56.8) 480 (56.3)
14 days before treatment 0.36 (0.13 to 0.96) —
Days after treatment:
 1-14 1.49 (0.91 to 2.44) 1.04 (0.63 to 1.71)
 15-30 1.25 (0.75 to 2.08) —
 31-90 1.21 (0.92 to 1.59) —
 91-365 1.06 (0.91 to 1.24) —
 366-730 0.94 (0.81 to 1.08) —
 731-1095 1.14 (0.98 to 1.31) —
Days 1-14=current use; days 15-30=recent use; days 31-1095=past use.
*Age at study start date for self controlled case series and at event date for case crossover study.
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because of its widespread use. A significantly higher 
risk of cardiovascular mortality was observed among 
the clarithromycin group in the CLARICOR (Effect of 
Clarithromycin on Mortality and Morbidity in Patients 
with Ischemic Heart Disease) trial during the follow-up 
period of 2.6 years, using public registers to ascertain 
outcomes.4  Notably, the agreement between hospital 
discharges and cause of death were 74% and 60%, 
respectively, compared with formal adjudication.31 
A recent cohort study by Svanstrom and colleagues also 
found that use of clarithromycin increased the risk of 
cardiovascular events in patients with acute exacerba-
tions of chronic obstructive pulmonary disease and 
community acquired pneumonia over one year.9  In 
addition, the association between the use of clarithro-
mycin and cardiovascular mortality was significant in 
patients with chronic obstructive pulmonary disease 
over one year. These two studies recruited patients with 
a high baseline cardiovascular risk, such as coronary 
heart diseases, chronic obstructive pulmonary disease, 
and community acquired pneumonia. This might reflect 
the fact that long term cardiovascular events and mor-
tality associated with clarithromycin merely affect a 
selected population, as we could find no long term car-
diovascular effect among the general population. Nev-
ertheless, this might also reflect important underlying 
comorbidities between treatment groups that could not 
be fully addressed in those studies rather than a causal 
effect. Importantly, the study did not report non-cardio-
vascular mortality as a negative control outcome.9 
Without this important information, the findings might 
be subject to important residual bias. We highly recom-
mend that future studies should report control out-
comes to detect residual confounding.
implications of this study
The estimated absolute risk difference associated with 
current use of clarithromycin compared with amoxicil-
lin in this study was 0.95 excess cardiac deaths per 1000 
patients. Notably, the rate of cardiac mortality was 118.7 
per 1000 person years in patients aged 75 or more 
receiving amoxicillin, considerably higher than that of 
patients aged 40-74 receiving amoxicillin (12.9 per 1000 
person years). Moreover, we classified current use as 
treatment lasting for 14 days, which would also double 
the estimates of absolute risk difference when com-
pared with classifying current use as a duration of 
seven days. As our study comprised patients aged 75 or 
more (35% of our cohort) and used a longer follow-up 
period as current use, our estimate was noticeably 
higher than the one estimated by Svanstrom and col-
leagues (37 per million courses).8 In our subgroup anal-
ysis, 2.63 excess cardiac deaths and 5.77 excess 
myocardial infarction per 1000 patients were observed 
among patients aged 75 or more. In addition, absolute 
risk differences of cardiac death and myocardial infarc-
tion were also higher among patients with hypertensive 
diseases or diabetes mellitus. Before prescribing clari-
thromycin, the cardiovascular risk profile of individual 
patients, especially those aged 75 or more or with 
comorbidities, should be assessed carefully.
Strengths and limitations of this study
We used both a population based cohort study with a large 
cohort size, representative of the Hong Kong population, 
and a case only design, which renders the underlying dif-
ferences between people less important. Accurate ascer-
tainment of incident myocardial infarction and cardiac 
deaths was possible by linking data in the clinical data 
analysis and reporting system within primary, secondary, 
and tertiary healthcare services and death registries. The 
positive predictive value of myocardial infarction was 
high; our estimate was similar to most of the high quality 
validation studies on myocardial infarction.32  However, 
the current study has several limitations. Firstly, we did 
not include lifestyle risk factors such as smoking, alcohol 
consumption, and physical activity in the propensity score 
modelling. However, we introduced variables such as 
chronic obstructive pulmonary disease, diabetes, and 
other chronic diseases in the model that might partly rep-
resent the effects of these risk factors. Although the 
absence of this information may affect the performance of 
propensity score modelling in the cohort analysis, it is 
unlikely to significantly alter the findings on acute cardio-
vascular effects in the self controlled case series analysis. 
We were unable to obtain data on whether a drug was 
actually taken or when it was taken. Thus the true use of 
the drug is unknown and may result in some bias. In addi-
tion, details on cause of death were not available for some 
patients and therefore could have affected the cause spe-
cific analyses. This applied to about only 10% of deaths in 
this study, and thus would not have led to substantial bias. 
Moreover, only the cases from the Hong Kong west cluster 
were validated in this study. However, the coding practice 
is unlikely to differ between individual patients and 
between hospitals that are managed by the same statutory 
organisation. The positive predictive value of arrhythmia 
was relatively low, such that some of the outcomes we 
included may not have been true arrhythmias. This error 
would tend to underestimate any genuine causal associa-
tion, assuming the likelihood of diagnostic  inaccuracy 
was the same for both clarithromycin users and amoxicil-
lin users. It may result from a low incidence of cardiac 
arrhythmia and less stringent diagnostic criteria when 
compared with myocardial infarction and stroke. Simi-
larly, some studies also reported a wide range of positive 
predictive values of cardiac arrhythmia or cardiac arrest in 
different databases.33-35
Conclusion
In this study no long term cardiovascular risk was asso-
ciated with clarithromycin but there was a suggestion of 
an increased short term risk of myocardial infarction, 
arrhythmia, and cardiac death associated with current 
use of clarithromycin among the Hong Kong popula-
tion. Given the acute risk, clarithromycin should be pre-
scribed with caution, especially to patients with a high 
baseline cardiovascular risk.
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